Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more 禄Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
City-born architect lists inspiration behind his designs in a new book
Digitization helps preserve, disseminate intangible cultural heritage
Sunday
- Subscribe
Related News
Home 禄 Business 禄 Manufacturing
Long takeover battle looms
By Caroline Jacobs |
December 14, 2010, Tuesday
|
Print Edition
Print Edition
Sanofi-Aventis extended its US$18.5 billion cash offer for United States biotech group Genzyme until January 21 and left open the option to prolong it further, a sign the French drug maker is ready for a long battle.
Nearly 1 percent of Genzyme shareholders had tendered their shares to Sanofi's US$69-a-share offer before an initial deadline expired last Friday, Sanofi said in a statement yesterday.
Sanofi's efforts to buy Genzyme could continue until May, when the US firm holds its annual shareholder meeting, giving Sanofi a chance to try to overturn Genzyme's board.
Long takeover battles are not uncommon. US industrial gases company Air Products has been trying to buy Airgas since February, while in the drug sector, it took about eight months before Roche could buy the rest of Genentech it did not already own.
At any rate, analysts widely expect Sanofi can only get to purchase Genzyme if it improves its current offer. A Reuters poll in August suggested US$78 a share could succeed.
"It's a failure for Sanofi with regard to the number of shares tendered," said Jean-Jacques Le Fur, analyst at Oddo Securities. "Sanofi will need to pay up."
Nearly 1 percent of Genzyme shareholders had tendered their shares to Sanofi's US$69-a-share offer before an initial deadline expired last Friday, Sanofi said in a statement yesterday.
Sanofi's efforts to buy Genzyme could continue until May, when the US firm holds its annual shareholder meeting, giving Sanofi a chance to try to overturn Genzyme's board.
Long takeover battles are not uncommon. US industrial gases company Air Products has been trying to buy Airgas since February, while in the drug sector, it took about eight months before Roche could buy the rest of Genentech it did not already own.
At any rate, analysts widely expect Sanofi can only get to purchase Genzyme if it improves its current offer. A Reuters poll in August suggested US$78 a share could succeed.
"It's a failure for Sanofi with regard to the number of shares tendered," said Jean-Jacques Le Fur, analyst at Oddo Securities. "Sanofi will need to pay up."
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
